Upload medtechy
View 286
Download 0
Embed Size (px) 344 x 292 429 x 357 514 x 422 599 x 487
DESCRIPTION
Abbvie FDA Response
Citation preview
FDA Considerations For Regulation Of Nanomaterial Containing Products Nakissa Sadrieh, Ph.D. Office of Pharmaceutical Science, CDER, FDA
Global Medical Cures™ | Novel New Drugs- 2013 Summary CDER FDA
FDA Regulatory Perspective: Data Integrity Steve Wilson, Dr.P.H., CAPT USPHS Deputy Director, Division of Biometrics II, CDER/FDA NIH Roadmap Program Feasibility
1 Efficacy Results NDA 22092 (MTP-PE) Laura Lu Statistical Reviewer Office of Biostatistics FDA/CDER
Adverse Event Reporting at FDA, Data Base Evaluation and Signal Generation Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented
1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,
CDER New Drugs Program 2017 Update - Food … New Drugs Program: 2017 Update Patrick Frey Chief of Staff Office of New Drugs, CDER/FDA FDA/CMS Summit December 5 th, 2017 2 Housekeeping
FDA Sterile Drug Process Inspections-cder
FDA perspectives: Biosimilar Development with a Lens on Quality - … · 2015. 11. 19. · Steven Kozlowski, M.D. Director, Office of Biotechnology Products OPS/CDER / U.S. FDA FDA/PQRI
Chenxiong (Charles) Le, Ph.D. OBI/OB/OPaSS/CDER, FDA Cardiovascular and Renal Drugs
FDA/CDER SEND PilotFDA/CDER SEND Pilot - CDISC · FDA/CDER SEND PilotFDA/CDER SEND Pilot Lauren Murphree Mihalcik, Ph.D. Co-chair, IT Subcommittee, PTCC OND CDER FDAOND, CDER, FDA
Eileen Navarro MD, FACP Medical Officer, OCS, OTS, CDER, FDA · 2018-05-08 · OCS, OTS, CDER, FDA. 2 WHAT MEDICAL REVIEWERS CAN DO WITH STANDARDIZED DATA AND METADATA RECEIVED IN
Robert T. O’Neill , Ph.D. Director , Office of Biostatistics CDER, FDA
Analytical method validation · • FDA Guidance for Industry - Q2B Validation of Analytical Procedures: Methodology • FDA CDER reviewer guideline for validation of chromatographic
Ram C. Tiwari Associate Director Office of Biostatistics, CDER, FDA [email protected]
Accelerated Approval Update 2005 Ramzi Dagher, MD DDOP/OODP/CDER/FDA
· FDA – CDER – RedI: Focus on CGMP & FDA Inspections – Participant List These participants granted permission to share their contact information Eileen Zhou Research Associate
FDA CDER List of Guidance Documents 8-2010 UCM079645
cGMP in the USA Training by CDER FDA
Update from FDA CDER - FDA Law Blog...Aug 03, 2019 · Update from FDA CDER Theresa Mullin, PhD ... •Develop standards to more consistently gauge state of quality maturity observed
FDA CDER RedI: Focus on CGMP & FDA Inspections Participant ... · PDF fileFDA – CDER – RedI: Focus on CGMP & FDA Inspections – Participant List These participants granted permission
Trial Design Issues in SLE Joel Schiffenbauer FDA/CDER DAAODP
FDA cGMP Training Program cGMP in the USA Nicholas Buhay Deputy Director Division of Manufacturing & Product Quality Office of Compliance, CDER, FDA
2018 Results Conference Call - Polyphor...1 FDA CDER Pharmacology Review: application number 22-311, FDA CDER Clinical Pharmacology Review: application number 22-311, mean of studies
Design and Statistical Analysis of Thorough QT (TQT) Studies Yi Tsong, Ph.D., CDER/FDA Co-author – Joanne Zhang, Ph.D., CDER/FDA The opinions presented
Novo Nordisk's Victoza FDA CDER Proprietary Name Review
CDER Computational Science Center - c-path.org · Chuck Cooper, M.D. Computational Science Center Office of Translational Sciences CDER, FDA Computational Science Center: Leveraging
2016 CDISC Japan Interchange Program CDISC Japan Interchange Program.pdfFDA-CDER Presentation Dr. Stephen Wilson, Director, Division of Biometrics III, FDA-CDER FDA-CDER Presentation
Steve Wilson, DrPH (Biostatistics) Deputy Director, Division of Biometrics II, CDER, FDA
1 ODAC September 13 th, 2005 Tarceva ® (erlotinib) Adrian Senderowicz, M.D. DDODP, CDER FDA
